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APOBEC3B-mediated corruption of the tumor
cell immunopeptidome induces heteroclitic
neoepitopes for cancer immunotherapy
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APOBEC3B, an anti-viral cytidine deaminase which induces DNA mutations, has been
implicated as a mediator of cancer evolution and therapeutic resistance. Mutational plasticity
also drives generation of neoepitopes, which prime anti-tumor T cells. Here, we show that
overexpression of APOBEC3B in tumors increases resistance to chemotherapy, but simul-
taneously heightens sensitivity to immune checkpoint blockade in a murine model of mela-
noma. However, in the vaccine setting, APOBEC3B-mediated mutations reproducibly
generate heteroclitic neoepitopes in vaccine cells which activate de novo T cell responses.
These cross react against parental, unmodified tumors and lead to a high rate of cures in both
subcutaneous and intra-cranial tumor models. Heteroclitic Epitope Activated Therapy
(HEAT) dispenses with the need to identify patient specific neoepitopes and tumor reactive
T cells ex vivo. Thus, actively driving a high mutational load in tumor cell vaccines increases
their immunogenicity to drive anti-tumor therapy in combination with immune checkpoint
blockade.
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Mutational plasticity of tumors drives malignancy andescape from therapy. In addition to exogenous sourcesof DNA damage such as radiotherapy and chemother-
apeutics1,2, the APOBEC3 proteins have been shown to be
endogenous drivers of genetic heterogeneity in part through their
activity as cytidine deaminases3–7. In humans there are seven
APOBEC3 family members (APOBEC3 A, B, C, D, F, G, and H),
while in mice there is one APOBEC3 gene8. APOBEC proteins
primarily function as host defenses against pathogens and are
tightly regulated under normal conditions9–11. In particular,
APOBEC3B expression is upregulated in multiple cancer types, is
associated with the burden of signature C to T mutations, and
with poor prognosis and therapeutic resistance9–14. We, and
others, have shown that high APOBEC3B expression increases
escape from oncolytic virotherapy, immunotherapy, and che-
motherapy15,16. Generally, therefore, high mutational plasticity in
tumor cells is regarded as deleterious and many strategies aim to
limit ongoing cancer mutation17.
However, it is also now clear that high mutational loads within
tumor cells correlate well with response to cancer immunother-
apy, especially immune checkpoint blockade (ICB)18–20. Thus,
mutation of either passenger or cancer-driving genes generates
novel neoepitopes presented by tumor cells. These neoepitopes
may be sufficiently different from the unmutated, self-epitopes to
prime, and activate, pre-existing T cells which have not been
tolerized, or deleted, and which can lead to potentially clearative
antitumor T-cell responses21–24. Neoepitopes are encoded by
nonsynonymous mutations, splice variants, or genome rearran-
gements that transform a self-peptide into a nonself peptide, and
their identification, and approaches to specifically activate their
cognate T cells, have provided effective clinical therapy25. How-
ever, the vast majority of neoepitopes are patient specific, with
very few shared neoantigens expressed between patients. There-
fore, T cells against each neoepitope must be raised on a patient-
by-patient basis, usually from a screen of multiple mutations
within the patient’s tumor cells, which is time, labor, and cost
intensive, thereby limiting their broad applicability.
Exploitation of mutation-induced neoepitopes raises the
somewhat counterintuitive possibility that actively driving
mutation within cancer cells, rather than inhibiting it, may lead
to tumor clearance by sensitizing tumors to immunotherapies.
While other groups have explored this idea in the context of
inactivation of DNA repair24, direct comparisons between the
deleterious effects of inducing treatment-resistance through
mutation, compared to the beneficial consequences of immune-
enhancing mutational activity, have not been widely performed.
Since APOBEC3B is a driver of cancer genomic diversity, we
hypothesize that its over-expression may have two ther-
apeutically opposing consequences. In the first, actively driving
mutation of the cellular transcriptome will generate clones
which are more aggressive and can evade therapy. Conversely,
APOBEC3B-mediated mutation of the cellular immunopepti-
dome might generate neoepitopes which will prime T-cell
responses against the newly immunogenic tumor cells. This
hypothesis is consistent with data showing that APOBEC3B
expression correlates with increased frequency of tumor infil-
trating lymphocytes3–5,16,26. In addition, a subset of these novel
neoepitopes may represent heteroclitic peptides which prime
T cells that recognize both the neoepitope and the unmutated
epitope from which it was derived27,28, consistent with data
showing that xenogeneic peptides can generate strong immune
responses against native antigens27–32. Whereas the priming of
T cells reactive only against de novo neoepitopes will allow
immune clearance only of APOBEC3B-modified tumor cells
themselves, priming of T cells by heteroclitic neoepitopes will
allow for bystander clearance of both APOBEC3B-modified, as
well as parental, unmodified tumor cells.
We show here that overexpression of APOBEC3B in tumors
both increases their ability to evade chemotherapy but also
simultaneously confers significantly heightened sensitivity to
immunotherapy with ICB, such that tumor cures are achieved in
an otherwise very poorly immunogenic murine melanoma tumor
model. We also show that APOBEC3B-mediated mutations
reproducibly generate novel heteroclitic neoepitopes which acti-
vate de novo T-cell responses reactive against the parental,
unmodified tumors which are significantly enhanced in their
potency by ICB. Finally, we demonstrate that human tumors can
be modified through APOBEC3B expression, leading to enhanced
T-cell recognition, thereby opening the path to clinical translation
but only in a tumor cell vaccine setting, in which the chances of
inducing any negative effects through APOBEC3B-mediated
induction of increased malignancy would be abrogated by use
of irradiated cell vaccines. Thus, the tumor-promoting effects of
driving mutation can be uncoupled from its immunogenicity-
enhancing effects through the use of heteroclitic epitope activated
therapy (HEAT). HEAT is broadly applicable to the treatment of
cancers of different histological types and locations and does not
require identification of specific neoepitopes on a patient-by-
patient basis.
Results
APOBEC3B expression and ICB promotes antitumor respon-
ses. We tested the hypothesis that APOBEC3B overexpression
drives mutations with the potential to introduce neoepitopes
which could be recognized by cognate T cells. B16 melanomas
stably expressing the HSVtk (Herpes Simplex Thymidine kinase)
suicide gene and either wild-type, active APOBEC3B (APO-
BEC3BACTIVE) or the catalytically inactive APOBEC3B mutant
(APOBEC3BINACTIVE)33 were established by subcutaneous
injection of the respective tumor cells and allowed to establish for
7 days. Tumor bearing mice were then treated with ganciclovir
(GCV) prodrug therapy, followed by anti-CTLA4 checkpoint
inhibitor therapy (Fig. 1a). Although GCV extended survival over
untreated controls (Fig. 1b, c) (p= 0.001 Log-Rank test with
Holm–Bonferroni correction for multiple comparisons), APO-
BEC3BACTIVE tumors escaped therapy more quickly than APO-
BEC3BINACTIVE tumors (Fig. 1b, c) (p= 0.286 Log-Rank test
with Holm–Bonferroni correction for multiple comparisons).
Sequencing of the HSVtk gene in the escaped tumors revealed a
consistent C-to-T APOBEC3B-signature mutation at base 21,
resulting in a premature stop codon. Anti-CTLA4 therapy
extended the median survival of mice bearing GCV-treated
APOBEC3BINACTIVE tumors (Fig. 1b, left inset), confirming that
HSVtk-mediated cell killing is immunogenic34. However, anti-
CTLA4 transformed the less-effective GCV therapy for APO-
BEC3BACTIVE tumors into a sustained, curative treatment
(Fig. 1b, right inset) (p= 0.0045 Log-Rank test with
Holm–Bonferroni correction for multiple comparisons). These
data show that while APOBEC3B overexpression drives tumor
escape from targeted small molecule therapy, it also significantly
enhances recognition and rejection by the immune system in the
context of ICB.
APOBEC3B overexpression and ICB improves vaccine efficacy.
To exploit the mutational burden generated by APOBEC3B
expression without contributing to tumor evolution, we generated
an APOBEC3B-modified tumor vaccine. Mice bearing sub-
cutaneous B16 parental tumors were treated with B16 cell lysates
retrovirally transduced to express either APOBEC3BACTIVE or
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Fig. 1 APOBEC3B expression enhances tumor escape but sensitizes tumors to immune checkpoint blockade therapy. a On day 0, 2 × 105 B16TK cells
expressing either APOBEC3BINACTIVE or APOBEC3BACTIVE were subcutaneously implanted into the right flank of C57Bl/6 mice. Two 5-day courses of
GCV therapy (50mg/kg i.p.) were administered from days 7 to 11, and 14 to 18, followed by anti-CTLA4 antibody or control IgG (5 mg/kg i.p.) on days 21,
23, and 25. b, c Mice were treated according to the regimen in (a) (n= 7 mice/group) tumor volumes were measured three times per week (c) and
sacrificed when tumors grew above 1 cm in length or width. Representative of three separate experiments. Groups were compared using a Log-Rank test
with Holm–Bonferroni correction for multiple comparisons.
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APOBEC3BINACTIVE, followed by anti-PD1 or control immu-
noglobulin (IgG) (Fig. 2a). The APOBEC3BACTIVE vaccine alone
significantly delayed tumor growth (Fig. 2b) and prolonged sur-
vival (Fig. 2c) compared to the B16-APOBEC3BINACTIVE vaccine
(p= 0.0005 Log-Rank test with Holm–Bonferroni correction for
multiple comparisons). However, the addition of anti-PD1, anti-
CTLA-4, or both ICB therapies induced complete and sustained
tumor regressions in mice treated with the B16-
APOBEC3BACTIVE vaccine, but not in mice treated with the
B16-APOBEC3BINACTIVE vaccine (Fig. 2c, d) (p= 0.0008 Log-
Rank test with Holm–Bonferroni correction for multiple com-
parisons). B16 tumor vaccines administered to mice bearing
subcutaneous TC2 syngeneic prostate tumors were ineffective,
even with APOBEC3BACTIVE/anti-PD1 therapy (Fig. 2c), sug-
gesting the induced T-cell response reflected the specific immu-
nopeptidome of the vaccine. We did not observe any symptoms
of autoimmunity in any of these experiments.
Vaccination elicits a T and NK cell antitumor response.
Depletion of CD4, CD8, and NK cells significantly reduced the
efficacy of B16-APOBEC3BACTIVE/anti-PD1 therapy (Supple-
mentary Fig. 1A) (p= 0.0004, 0.0008, and 0.026, respectively Log-
Rank test with Holm–Bonferroni correction for multiple com-
parisons) and 7 of 7 mice which rejected their primary tumors in
Supplementary Fig. 1 following treatment with B16-
APOBEC3BACTIVE+ α-PD1 also rejected a further re-challenge
with 2 × 105 parental B16 cells on the opposite flank at day 150
post primary challenge, indicating the induction of a memory T-
cell response.
When cocultured in vitro with parental, unmodified tumor
cells, splenocytes from mice which received B16-
APOBEC3BACTIVE vaccines secreted significantly more inter-
feron gamma (IFNγ) than mice treated with B16-
APOBEC3BINACTIVE (Supplementary Fig. 1B) (p < 0.05). The
in vitro recall response was significantly increased when B16-
APOBEC3BACTIVE vaccination was combined with ICB in vivo.
Adoptive transfer of CD8 T cells from mice treated with the B16-
APOBEC3BACTIVE/anti-PD1 vaccine, but not the B16-
APOBEC3BINACTIVE/anti-PD1 vaccine, conferred partial protec-
tion against parental B16 tumors (Supplementary Fig. 1C) (p=
0.0009 Log-Rank test with Holm–Bonferroni correction for
multiple comparisons).
APOBEC3B vaccine is therapeutic in a brainstem glioma
model. Mice bearing brainstem-implanted GL261 tumors were
treated with GL261-APOBEC3BACTIVE or GL261-
APOBEC3BINACTIVE-modified GL261 vaccines (Fig. 3a). Mice
treated with the GL261-APOBEC3BACTIVE-modified vaccine
survived significantly longer than untreated controls (Fig. 3b)
(p= 0.0015 Log-Rank test with Holm–Bonferroni correction for
multiple comparisons). The GL261-APOBEC3BACTIVE/anti-PD1
vaccine doubled median survival, although when controlling for
multiple comparisons this did not reach statistical significance
compared to untreated controls (p= 0.076 Log-Rank test with
Holm–Bonferroni correction for multiple comparisons). How-
ever, the combination of anti-CTLA4 and anti-PD1 therapy with
the GL261-APOBEC3BACTIVE vaccine significantly improved
survival compared to mice treated with control immunoglobulin,
with all mice surviving past 40 days (p= 0.0012 Log-Rank
test with Holm–Bonferroni correction for multiple comparisons).
Splenocytes from mice treated with the GL261-
APOBEC3BACTIVE vaccine with ICB secreted significantly
increased levels of IFNγ on restimulation with parental GL261
tumors compared to mice receiving only the GL261-
APOBEC3BACTIVE vaccine (Fig. 3c) (p < 0.01 one-way
ANOVA). These data show that the APOBEC3BACTIVE-mod-
ified vaccine and ICB strategy is effective against a second tumor
type and retains efficacy in the immunologically distinct site of
the brainstem.
APOBEC3B induces heteroclitic neoepitopes. We have pre-
viously shown that vesicular stomatitis virus (VSV) infection of
B16tk-APOBEC3BACTIVE cells led to enhanced escape from
oncolytic VSV therapy compared to B16tk-APOBEC3BINACTIVE
cells, highlighting the role of APOBEC3B in evading primary
therapies16. A whole-genome sequencing screen of the B16tk-
APOBEC3BACTIVE-modified, VSV-escaped population, com-
pared to B16tk parental cells, identified over 1,000,000 mutations
or indels unique to the B16-APOBEC3BACTIVE overexpressing
cells (SRA Submission: SRP159367). Using an in vitro cytidine
deamination assay (Supplementary Fig. 2A), we confirmed that,
whereas the APOBEC3BACTIVE vector induced cytidine deami-
nase activity consistent with APOBEC mutagenesis, the APO-
BEC3BINACTIVE vector did not. Consistent with these data, whilst
we detected APOBEC3B-signature mutations in the B16-
APOBEC3BACTIVE cells, these were not, or very rarely, present
in the corresponding B16-APOBEC3BINACTIVE cells (Fig. 4b).
However, in addition to core, APOBEC3B-signature mutations,
multiple accessory mutations were also generated in the APO-
BECACTIVE cells compared to the APOBECINACTIVE cells,
including nucleotide changes and indels which occurred typically
at low clonalities in the vaccine cells (Supplementary Fig. 2B). Of
the ~1,000,000 total mutations detected by NGS in the B16-
APOBEC3BACTIVE cells, about 68,000 contained the classical
APOBEC mutational signature. Of these ~68,000 mutations, 244
resulted in predicted amino acid changes in expressed proteins
through C to T or G to A transitions leading to missense
mutations consistent with APOBEC3B mutational activity (Sup-
plementary Data 1)35. These mutations were converted into 21-
amino acid sequences, with 10 amino acids flanking the muta-
tional site (Supplementary Data 2). Totally, 8–10 mer peptides
were generated from these sequences, placing the mutated amino
acid in every position from the amino terminal to the carboxy
terminal end. These peptides were then filtered through an MHC
binding affinity algorithm (Supplementary Table 1). Because our
depletion studies showed that CD8 T cells were critical for
therapy, we hypothesized that a proportion of APOBEC3B-
induced neoepitopes in the vaccine cells would also act as het-
eroclitic peptides and screened the potential neoepitopes for
differential binding to MHC Class I29. Thresholds were set for
binding affinity to either H2Kb (Fig. 4a, dark gray and dark blue)
or H2Db (Fig. 4a, light gray and light blue), such that wild-type
peptide binding was above 500 nM, while APOBEC3B-mutated
peptide binding was below 500 nM36,37. By refining this list using
the EMBL-EBI Expression Atlas, eight candidate proteins were
identified that are expressed in the skin: Ahctfl, C77080, Csde1,
Fcgbp, Plbd2, Smc4, Stag2, and Xpo1 (which contained three
candidate peptide sequence variants) (Fig. 4a). Of these
APOBEC-characteristic mutations, none were present clonally in
the B16-APOBECACTIVE vaccine population (Fig. 4b) and varied
in frequency between ~60 and <10%. Only one of the mutations
(Stag2) could be detected by NGS to be present in the
ABPOC3BINACTIVE cells, whereas all of the others were induced
by de novo APOBEC3B activity.
In vitro validation of APOBEC3B-induced neoepitopes. B16
cell lines were generated that transiently overexpressed the ten
wild-type (B16-WT sequence) peptides or the mutant potential
neoepitope peptides (B16-APOBEC3B-modified sequence).
Expression constructs contained the ten wild type, or neoepitope,
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Fig. 2 APOBEC3B enhances B16 cell lysate vaccine and synergizes with immune checkpoint blockade therapy. a On day 0, 2 × 105 B16 murine
melanoma or TC2 murine prostate carcinoma were implanted subcutaneously into the right flank of C57Bl/6 mice. One 5-day course of APOBEC3BACTIVE
or APOBEC3BINACTIVE-modified B16 cell vaccines (freeze/thaw lysate of 106 cells i.p.) was administered from days 5 to 9. This was followed by anti-PD1
antibody or IgG control (12.5 mg/kg i.p.) on days 12, 14, 16, 19, 21, and 23. b Mice (n= 8/group) were treated according to the regimen in (a) and tumor
volumes were measured three times per week. c Kaplan–Meier survival curves representing experiment described by (a) and (b). Representative of 5
experiments. d Treatment of subcutaneous B16 murine melanomas as in (a), except with the addition of anti-CTLA4 antibody (5 mg/kg i.p.) as a
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groups of 7 mice treated with B16-APOBEC3BACTIVE vaccine with anti-PD1, anti-CTLA4, or anti-PD1/anti-CTLA4 antibody therapy that all had 100%
survival at 150 days. This experiment was repeated once. Groups were compared using a Log-Rank test with Holm–Bonferroni correction for multiple
comparisons.
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peptides separated by Ala-Ala-Tyr (AAY) spacers and tagged
with an N-end degron motif to increase MHC Class I presenta-
tion (Fig. 4c)38,39. Splenocytes from unvaccinated or B16-
APOBEC3BINACTIVE vaccine-treated mice showed no IFNγ
recall response to cells overexpressing B16-WT peptides or
B16-APOBEC3B-modified peptides (Fig. 4d). Splenocytes from
B16-APOBEC3BACTIVE vaccine-treated mice—but without anti-
PD1 ICB—secreted very low levels of IFN-γ in response to res-
timulation with B16 cells expressing only wild-type epitopes
(Fig. 4d) (p < 0.0001 two-way ANOVA). In contrast, splenocytes
from B16-APOBEC3BACTIVE vaccine-treated mice secreted sig-
nificantly higher levels of IFN-γ in response to restimulation with
B16 cells expressing the string of APOBEC3B-modified epitopes
described in Fig. 4c. These data suggest that APOBEC3B mod-
ification of B16 cells induces mutations which stimulate T-cell
responses against at least one of the epitopes included in the
APOBEC3B string.
Therefore, expression constructs were created for each of the
individual neoepitopes. As before (Fig. 4d), splenocytes from
naïve mice, or from mice vaccinated with the B16-
APOBEC3BINACTIVE vaccine, did not generate a recall response
against parental B16 tumor cells in vitro (Fig. 4e). However,
splenocytes from B16-APOBEC3BACTIVE vaccine-treated mice—
and in the presence of anti-PD-1 ICB—secreted significant levels
of IFN-γ in response to restimulation with parental B16 cells, or
parental B16 cells expressing only wild-type epitopes (Fig. 4e).
These data show that the addition of anti-PD1 ICB enhances the
recognition of self, unaltered epitopes by T cells raised against
APOBEC3B-mutated neo-epitopes. Moreover, these splenocytes
also secreted significantly higher levels of IFN-γ in response to
restimulation with B16 cells expressing the string of APOBEC3B-
modfied epitopes (consistent with Fig. 4d in the absence of ICB).
This increased recognition of B16 cells by the expression of the
string of APOBEC3B-modified epitopes was only reproduced by
single epitope expression of the APOBEC3B-modified cold shock
domain-containing E1(CSDE1*) epitope but not the wild-type
CSDE1 epitope (Fig. 4d). Overexpression of none of the
remaining nine potential predicted APOBEC3B-modified neoe-
pitopes enhanced the recall response above that seen in response
to parental B16 cells themselves (Fig. 4e). These data confirm that
treatment with the B16-APOBEC3BACTIVE vaccine and anti-PD1
induced T-cell responses against parental B16 tumors and suggest
that an APOBEC3B-mutated neoepitope within CSDE1 may
function as a heteroclitic neoepitope.
To validate that the putative CSDE1 heteroclitic neoepitope was
indeed present in the vaccine preparation, we sequenced the CSDE1
gene in B16-APOBEC3BACTIVE vaccine cells used in Figs. 2 and 3.
Consistent with the lack of APOBEC3B deaminase activity of the
APOBEC3BINACTIVE construct (Supplementary Fig. 2A), B16
parental and B16-APOBEC3BINACTIVE cell vaccines contained
only the wild-type ATGAGCTTTGATCCA sequence (Fig. 5a, b).
However, the vaccine preparation contained a mixed population of
cells carrying either the wild-type ATGAGCTTTGATCCA
sequence, as found homogeneously in the parental B16 and B16-
APOBEC3BINACTIVE vaccine populations, or the mutated
ATGAGCTTTGATTCA sequence (Fig. 5c), which encodes the
potentially heteroclitic CSDE1 neoepitope (Fig. 4e). We further
validated that the CSDE1 mutation is a reproducible and consistent
target of APOBEC3B activity in B16 cells in two additional vaccine
preparations (Supplementary Fig. 3).
The CSDE1 heteroclitic neoepitope primes anti-B16 T cells.
B16 cells transfected with the APOBEC3B-mutated CSDE1 epi-
tope (CSDE1*), or the wild-type parental epitope (CSDE1), were
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Fig. 3 APOBEC3B-modified GL261 cell lysate vaccine also effective
against orthotopic gliomas. a Treatment strategy from (Fig. 2a) was
adapted to target GL261 murine gliomas. In summary, on day 0, 5 × 104
GL261 murine glioma cells were implanted into the brainstem of C57Bl/6
mice. One 5-day course of APOBEC3BACTIVE or APOBEC3BINACTIVE-
modified GL261 cell vaccines (freeze/thaw lysate of 106 cells i.p.) was
administered from days 5 to 9. This was followed by anti-PD1 antibody,
anti-CTLA4 antibody or IgG control (12.5 mg/kg i.p.) on days 12, 14, 16, 19,
21, and 23. b Kaplan–Meier survival curves representing experiment
described by (a) (n= 7 mice/group). Representative of three separate
experiments. Groups were compared using a Log-Rank test with
Holm–Bonferroni correction for multiple comparisons. c Spleens and lymph
nodes obtained from mice treated with GL261-APOBEC3BACTIVE
vaccination and/or antibody-mediated checkpoint inhibition were made
into single-cell suspensions and cocultured with GL261 target cells for 72 h.
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used as a vaccine in combination with anti-PD1 to treat parental
B16 tumors in the flank or brainstem. Mice vaccinated with B16
cells expressing CSDE1 succumbed to disease at the same time as
untreated controls (Fig. 5d, e) (p= 0.7805 and 0.158 Log-Rank test
with Holm–Bonferroni correction for multiple comparisons). B16
cells expressing CSDE1* generated partial therapy (p= 0.0009 and
0.002 Log-Rank test with Holm–Bonferroni correction for multi-
ple comparisons), whereas the B16-APOBEC3BACTIVE vaccine
was significantly more effective, highlighting the value of vacci-
nation with a wide range of antigens to prevent tumor escape (p=
0.0442 and 0.001 Log-Rank test with Holm–Bonferroni correction
for multiple comparisons). When splenocytes from these mice
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were cocultured with either parental B16 or TC2 prostate tumor
cells expressing either CSDE1 or CSDE1* epitopes, only mice
vaccinated with B16-CSDE1* and treated with ICB showed an
IFNγ recall response against parental B16 cells (Fig. 5f) (p < 0.01
one-way ANOVA). Most importantly, in the context of an
irrelevant TC2 tumor, mice vaccinated with B16-CSDE1* reacted
against both the TC2-expressed CSDE1* and, albeit to a lesser
extent, against the CSDE1 epitope, thereby confirming that the
APOBEC3B-mutated CSDE1* acts as a heteroclitic peptide (p <
0.001 one-way ANOVA).
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Human reactivity to APOBEC3B-modified tumors. Our murine
data above justifies the clinical translation of APOBEC3B-
modification of tumor cells as cancer vaccines. To validate this
approach, human melanoma cells, APOBEC3B-modified or
controls, were cocultured in vitro with activated human CD3
T cells for 10 days. Following this period of exposure to putative
antigens presented by melanoma cells, the T cells were restimu-
lated with unmodified tumors and assayed for interferon-gamma
(IFNγ) secretion, proliferation, and target cell killing (Fig. 6a). As
a mimic of the clinical scenario in which a patient’s own tumor
cells would be used as the platform for the APOBEC3B-modified
vaccine, Mel888-APOBEC3BACTIVE or Mel888-GFP cells were
used to educate donor T cells against unmodified Mel888 cells.
Consistent with our murine data, while T-cell activation in the
presence of Mel888-GFP cells induced IFNγ secretion, pro-
liferation, and tumor killing, Mel888-APOBEC3BACTIVE cocul-
ture significantly enhanced each of these T-cell functions (Fig. 6b)
(p= 0.00636, 0.00285, and 0.00479, respectively Student’s t test).
Addition of anti-PD1 checkpoint antibodies further increased
T-cell activity both in cells educated by GFP- (p= 0.00468 and
p= 0.01996) and APOBEC3BACTIVE-modified Mel888 tumors
(p= 0.49602 and p= 0.0233 Student’s t test).
Finally, and also consistent with our murine data, we
confirmed that the use of APOBEC3B modification to stimulate
human antitumor T-cell responses was applicable across tumor
types. In vitro activated T cells were cocultured with autologous,
monocyte-derived dendritic cells pulsed with lysates from either a
GFP-modified human pediatric glioma cell line (SJPDGF1), with
lysate from the APOBEC3BACTIVE-modified SJPDGF1 equiva-
lent, or with lysate of APOBEC3BACTIVE-modified Mel888 cells.
These in vitro primed T cells were then restimulated with
dendritic cells pulsed with unmodified SJPDGF1 lysate (Fig. 6c).
T cells primed with DC pulsed with SJPDGF1-
APOBEC3BACTIVE-modified lysate secreted increased levels of
IFNγ compared to irrelevant (Mel888) or unmodified (SJPDGF1)
tumor lysates, which further increased in the presence of anti-
PD1 antibodies (Fig. 6d). Together, these data show that
APOBEC3B-modification enhances the immunogenicity of
human tumor cells for T-cell recognition and that such an
approach can potentially be translated clinically in the context of
an autologous vaccine platform.
Discussion
Cancer evolution is driven by somatic mutation, leading to
selection of subpopulations which become progressively more
malignant and which can evade therapy40,41. Generally, therefore,
high mutational plasticity is regarded as deleterious. However,
mutational plasticity also generates neoepitopes, which can prime
antitumor T-cell responses21–24. Therefore, we tested here the
controversial concept that instead of preventing ongoing mutation
in tumor cells, actively driving a high mutational load through
APOBEC3B expression may enhance therapy by rendering poorly
immunogenic tumors susceptible to immunotherapy.
As expected, B16tk tumors expressing APOBEC3B (APO-
BEC3BACTIVE) were more resistant to frontline GCV che-
motherapy than control tumors, consistent with the mutagenic
activity of APOBEC3B selecting clones insensitive to GCV.
However, that same APOBEC3B mutagenesis also conferred
significantly heightened sensitivity to immunotherapy with ICB.
We hypothesize that APOBEC3B-induced mutations generated
neoepitopes which became potent targets for de novo T-cell
responses and that GCV-mediated killing enhanced the ability of
antigen presenting cells to present these neoepitopes to poten-
tially reactive T cells. Thus, loss of frontline therapy due to
mutation-driven resistance may be more than compensated for
by therapeutic gain from enhanced mutation-driven immuno-
genicity. These data open the way for new therapeutic approaches
based upon turning poorly immunogenic (cold) tumors into
highly immunogenic and well infiltrated (hot) tumors by actively
driving mutation to corrupt the cellular immunopeptidome and
express neoepitopes de novo.
However, this approach also risks simultaneously driving
treatment resistance and increased malignancy by mutation to
cancer driver genes. Therefore, we exploited the immunogenicity
of APOBEC3B-induced heteroclitic neoepitopes in the setting of a
therapeutic vaccine. In this model, T cells which escape central
tolerance and may be weakly reactive to self tumor antigens
would be activated by a heteroclitic neoepitope (induced by
APOBEC3B mutation) and react back against a host tumor
expressing the native protein27–32,42. APOBEC3B expression
would generate a library of mutated antigens, raising multiple
clones of tumor-reactive T cells, thereby reducing the chances of
antigen escape. Consistent with this hypothesis, the modest sur-
vival enhancement generated by the B16-APOBEC3BACTIVE
vaccine alone was converted into a curative treatment when
combined with ICB, dependent upon CD4, CD8, and NK cells.
Interestingly, even in the presence of ICB to overcome immu-
nosuppressive mechanisms acting on the activated antitumor
T-cell response43–46, we did not observe any signs of auto-
immunity. However, in each type of tumor which might be
treated by this approach, detailed preclinical histological and
toxicological studies should be performed to confirm that het-
eroclitic T-cell responses against APOBEC3B-mutated neo-epi-
topes do not raise autoreactive T-cell activity against critically
important self-peptide epitopes expressed on the corresponding
normal tissues.
Fig. 5 Sequencing of APOBEC3BACTIVE modified vaccines generates reproducible mutations in CSDE1. Sanger sequencing of CSDE1 from a parental B16
cells, b APOBEC3BACTIVE modified vaccine, and c APOBEC3BINACTIVE modified vaccine was performed. Figures are representative of three independent
experiments. Each preparation of the APOBEC3BACTIVE modified vaccine had proportions of cells containing a C or a T at the 13th base pair, corresponding
to the P5S amino acid change seen in Fig. 5 and Supplementary Fig. 2. (Figure was prepared using SnapGene software (from GSL Biotech; available at
snapgene.com). d On day 0, 2 × 105 B16 murine melanoma cells were implanted subcutaneously into the right flank of C57Bl/6 mice. Two 5-day courses of
B16-APOBEC3BACTIVE, B16-APOBEC3BINACTIVE, B16-CSDE1, or B16-CSDE1* vaccines (freeze/thaw lysate of 1 × 106 cells i.p.) were administered from days
5 to 9 and 12 to 16. This was followed by anti-PD1 antibody or IgG control (12.5 mg/kg i.p.) on days 12–16, 19, 21, and 23. Kaplan–Meier survival curves
representing experiment described. Representative of three separate experiments. e On day 0, 5 × 104 B16 murine melanoma cells were implanted into the
brainstem of C57Bl/6 mice. One 5-day course of B16-APOBEC3BACTIVE, B16-APOBEC3BINACTIVE, B16-CSDE1, or B16-CSDE1*-modified cell vaccines
(freeze/thaw lysate of 106 cells i.p.) was administered from days 5 to 9. This was followed by anti-PD1 antibody or IgG control (12.5 mg/kg i.p.) on days 12,
14, 16, 19, 21, and 23. Kaplan–Meier survival curves representing experiment described (n= 7 mice/ group). This experiment was repeated once. f Spleens
and lymph nodes obtained from mice treated with B16-CSDE1 or B16-CSDE1* vaccination and antibody-mediated checkpoint inhibition in (e) were made
into single-cell suspensions and cocultured with B16 or TC2 target cells expressing CSDE1 or CSDE1* for 72 h. Supernatant from the coculture was assayed
using a mouse interferon gamma ELISA. Data points represent three biologic replicates. Error bars indicate mean and SD. ANOVA was used followed by
Tukey’s multiple comparison test. **p≤ 0.01, ***p≤ 0.001.
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Our broadly mutated vaccine was also effective against gliomas
in the immunologically distinct location of the brainstem47–49.
The fact that anti-CTLA-4 improved vaccine efficacy in the B16
flank tumor model, but not in the GL261 intracranial model, is
consistent with ICB therapy against brain tumors being limited by
the ability of extracranially activated T cells to infiltrate into, and
remain active in, the brain50.
Our NGS revealed more than a million overall mutations in the
B16-APOBEC3BACTIVE cells compared to control cells (Supple-
mentary Fig. 2B). Of these, ~68,000 contained the classical
APOBEC signature/motif. In ongoing studies of mutagenesis of
the csde1 gene, we have observed induction of three mutations
within the csde1 gene which are detectable at levels of >20% in the
whole cell population within 48 h post transduction, during
which time APOBEC3B expression was still readily detected in
B16-APOBEC3BACTIVE cells. All three mutations have an
APOBEC mutational signature, and all three were undetectable in
B16 cells transduced with the APOBEC3BINACTIVE vector. In
contrast, we also detected one further mutation in the csde1 gene
in APOBEC3BACTIVE cells. However, this fourth mutation was
not detectable at any point up to 120 h post transduction—by
which time we could no longer detect APOBEC3B over-
expression in the cells. In contrast, this mutation was present in
the population at day 21 post transduction, suggesting that it was
generated subsequent to the direct mutagenic activity of APOBEC
expression. None of these four mutations were detected in the
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Fig. 6 Human reactivity to APOBEC3B-modified tumors. a CD3+ T cells from healthy donor PBMCs were isolated and activated with CD3/CD28 beads.
These T cells were cocultured with Mel888 cells previously transduced by lentivirus expressing GFP or APOBEC3B and pretreated for 12 h with human
interferon gamma (hIFNγ). After 10 days of co-incubation, CD3+ T cells were isolated, stained with cell trace violet, and replated with hIFNγ pretreated
Mel888 parental cells. After 3 days, supernatant was collected for hIFNγ ELISA, T cells underwent flow cytometric analysis for proliferation by cell trace
violet dilution, and Mel888 cells were counted to assess target killing. Representative of three separate experiments. b hIFNγ ELISA, T-cell proliferation,
and target killing from T cells cocultured with autologous Mel888 cells for both education and restimulation. Error bars indicate mean and SD. c Prior to
coculture, CD14+ cells were isolated from healthy donor PBMCs and matured into monocyte-derived dendritic cells. CD3+ T cells were isolated from the
same donor PBMCs and activated with CD3/CD28 beads. These T cells were cocultured with the mature dendritic cells and pulsed with pediatric glioma
(SJPDGF1) or Mel888 lysate previously transduced by lentivirus expressing GFP or APOBEC3B. Lysates were added again on days 2 and 3 of coculture.
Seven days later, CD3+ T cells were isolated, and cocultured with fresh monocyte-derived dendritic cells pulsed with parental SJPDGF1 lysate. Three days
later, supernatant was collected for hIFNγ ELISA. d hIFNγ ELISA from vaccination using Mel888 or SJPDGF1 lysate for education and SJPDGF1 lysate for
restimulation. All cocultures were performed at a 10:1 ratio of targets:effectors. Student’s t test was performed followed by Holm–Bonferroni correction for
multiple comparisons. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001.
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B16-APOBEC3BINACTIVE cells at any time points following
transduction. Based on these preliminary observations, we
hypothesize that the initial overexpression of APOBEC3B induces
a core set of mutations, carrying the classical APOBEC3B
mutational signature/motif, and often as a set of strand coordi-
nated mutations (kategeis)51. With time, these core mutations,
affect pathways in the cell which will, themselves, lead to further
cascades of mutations throughout the genome. With time, the
overall mutational activity seen in the cell population will reflect
the sum of the initial core APOBEC3B mutations/kategeis, along
with an amplification of the mutational burden through addi-
tional cascades of mutation resulting from the phenotypic effects
of the core mutations. This hypothesis is consistent with the
observed mutational activity of APOBEC in humans, where
APOBEC mutagenesis has been shown to induce mutations in
cancer driver genes in several different cancer types, which then
drive the transition to an increasing malignant phenotype
through additional mutation9,26,40,52–54. Moreover, APOBEC
activity has been shown to drive branched evolution through the
acquisition of sub-clonal mutations during the evolutionary
progression of a variety of human cancers55–57 which is con-
sistent with the presence of the sub-clonal, APOBEC signature
mutations that we detected in the B16-APOBEC3BACTIVE vac-
cine population (Supplementary Fig. 2B).
Using next generation whole-genome sequencing to identify
potential APOBEC3B-generated heteroclitic peptides, we selected
ten mutant skin-expressed peptides (generated from mutations
with APOBEC3B-like signatures) with increased MHC-I binding
affinity. Of these ten candidates, all but one of which were
identified from the NGS data to be present in the B16-
APOBEC3BACTIVE but not in the B16-APOBEC3BINACTIVE cell
vaccines (Fig. 4b), one mutant peptide derived from the CSDE1
protein stimulated an ex vivo recall response against parental B16
cells. CSDE1 is a multifunctional RNA binding protein that
regulates RNA translation and turnover58–62. B16 cell lysates
expressing the APOBEC3B-altered CSDE1 peptide, but not the
wild-type peptide, enhanced survival of tumor bearing mice when
combined with ICB, although less effectively than the
APOBEC3B-modified cell vaccine, highlighting the advantage of
a wide spectrum library approach63. Thus, we have shown that
mutated CSDE1 represents at least one of the directly
APOBEC3B-mutated genes which can contribute to the immu-
nizing potential of the B16-APOBEC3BACTIVE vaccine (Fig. 5).
However, our data also clearly show that the full immunizing
potential of the B16-APOBEC3BACTIVE vaccine is not recapitu-
lated solely by mutated CSDE1 (Fig. 5d, e). Therefore, it is highly
probable that additional mutations—both within the core
APOBEC3B-mediated mutational load, as well as within the
subsequent mutational amplification steps—also contribute to the
protective effects seen with the vaccine. We confirmed that the
mutated CSDE1 peptide was a heteroclitic epitope because sple-
nocytes from mice treated with B16-APOBEC3BACTIVE/ICB
secreted IFNγ in response to both the altered, and, critically, the
unaltered CSDE1 epitope, expressed in transfected TC2
prostate cells.
Our data show that APOBEC3B-induced mutations in the
vaccine cell population are not clonal and can be present at fre-
quencies of up to ~60% (Fig. 4b). This is significant because the
response of a tumor to immune checkpoint blockade is depen-
dent upon both the levels of mutation burden and the level of
clonal neoantigens present. Thus, if a given neoantigen is
expressed in only a proportion of the tumor, even a potent T-cell
response against that neoantigen will not clear the entire tumor
burden. Interestingly, the heteroclitic nature of a proportion of
the neoepitopes induced by APOBEC3B mutation may help, at
least partially, to overcome this problem. In this respect, if the
APOBEC3B-mutated vaccine induces several different heteroc-
litic neoepitopes, the T cells responding to these neoantigens will
also respond to the unmutated epitopes expressed on the parental
tumor cells, as we have shown here. Therefore, since it is likely
that a high proportion of the tumor cells will express the
unmutated epitope against which the T cell reactivity is induced,
the problem of a lack of clonal expression of a mutated neoepi-
tope within every cell of a tumor may be circumvented.
As shown in Supplementary Fig. 2, in addition to a core set of
characteristic APOBEC signature mutations, multiple accessory
mutations were also generated in the APOBECACTIVE cells
compared to the APOBECINACTIVE cells. These mutations
included indels which generated frameshift mutations which
might themselves generate novel antigens. It may be that such
new antigens would be less significant in the vaccine strategy we
describe here because the T-cell responses raised against com-
pletely novel antigens—generated by frameshift mutations—
would be unlikely to cross-react back against the parental tumors
in which the neoantigens are not expressed.
Finally, to support translation of APOBEC3B-modified human
tumor cell vaccines into clinical trials, we demonstrated that
human T cells activated in the presence of APOBEC3BACTIVE-
modified tumors of diverse types have increased reactivity to
unmodified tumors, that this is further enhanced with ICB, and
can be used in the context of pulsing human dendritic cells with
APOBEC3B-modified vaccines.
Our data here show that actively driving mutation in tumor
cells to enhance mutational load can be achieved using forced
overexpression of APOBEC3B. This generates a genome-wide
library of defined mutations, which can be tracked by their
characteristic mutational signature, and associated with different
phenotypes (Fig. 5 and Supplementary Fig. 3). Our data here also
show that, while APOBEC3B-driven mutation decreased sensi-
tivity to frontline chemotherapy, it simultaneously enhanced
sensitivity to checkpoint blockade immunotherapy. The overall
outcome was that the therapeutic gain in immunotherapy sig-
nificantly outweighed the loss of responsiveness to chemotherapy.
This concept opens up opportunities for a whole new approach to
cancer immunotherapy in which mutagenesis is actively driven
within tumors rather than inhibited. Current therapies based on
identification of neoepitopes are highly individualized, time,
labor, and cost intensive, and may not be readily applicable for
tumors with a low mutational burden. In contrast, we describe
here a readily translatable clinical method by which forced
expression of APOBEC3B in the context of an ex vivo generated
vaccine can induce an enhanced mutational load which combines
with immune checkpoint blockade for very potent cancer
immunotherapy. This is in sharp contrast to the risks of inducing
tumor cell escape from therapy, which has previously been the
hallmark of APOBEC3B mutagenesis. We also show that
APOBEC3B-driven mutagenesis generates a genomic library of
heteroclitic neoantigens that, while not expressed within the
in situ tumor, can induce antitumor immunity through activation
of reactive antitumor T cells, thereby significantly enlarging the
scope of available vaccine targets. Studies are currently underway
to determine whether APOBEC3B-mediated mutagenesis is
uniquely able to induce enhanced immunogenicity of tumor cell
vaccines or whether other mutagenic compounds/processes—
such as chemotherapy or radiation therapy—can have similar
effects.
Importantly, this HEAT will contain multiple neoepitopes of
which different subsets will also be heteroclitic for each individual
patient, both dispensing with the need to identify patient
specific neoepitopes, and overcoming the need for pre-existing
targetable mutations in the cancer genome. Nonetheless, exten-
sive additional preclinical studies will have to be conducted to
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assess the potential for autoimmune induction using such a
vaccine approach. In addition, the concept of direct transfer of
APOBEC3B into live tumor cells to induce immunogenicity
through formation of novel heteroclitic neo-epitopes cannot yet
be considered as a clinical option due to the risks of inducing
further tumor promoting mutations. Finally, we show that
APOBEC3B-induced heteroclitic neoepitope vaccines are effective
against different tumor types, growing in different anatomic
locations, indicating that this represents a technically simple,
widely applicable method to exploit neoepitopes for cancer
immunotherapy.
Methods
Study design. This study was designed to evaluate the use of an APOBEC3B-
modified vaccine to prolong survival of tumor bearing mice and investigate its
synergy with immune checkpoint blockade. Seven mice per group were used for
each experiment to achieve statistical power to make multiple comparisons. Mice
were randomized at time of tumor implantation and tumors were measured by a
single blinded individual.
Cell lines. B16.F1 murine melanoma cells were obtained from the ATCC. B16TK
cells were derived from a B16.F1 clone transfected with a plasmid expressing the
herpes simplex virus thymidine kinase (HSV-1 TK) gene in 1997/1998. Following
stable selection in 1.25 µg/mL puromycin, these cells were shown to be sensitive to
Ganciclovir (Cymevene) at 5 µg/ml [20–22]. B16TK cells were grown in DMEM
(HyClone, Logan, UT, USA)+ 10% fetal bovine serum (FBS) (Life Technologies)
+ 1.25 µg/mL puromycin (Sigma) until challenge. GL261 cells were obtained from
Dr. Aaron Johnson (Mayo Clinic) in 2014. TRAMP-C2 (TC2) cells are derived
from a prostate tumor that arose in a TRAMP mouse and were characterized as
described64,65. Mel888 cells were obtained from the Imperial Cancer Research
Fund (ICRF) in 1997/1998 and were grown in DMEM (Hyclone, Logan, UT, USA)
+ 10% FBS (Life Technologies). SJPDGF1 pediatric diffuse intrinsic pontine glioma
(DIPG) cells were a generous gift from Dr. Cynthia Wetmore (previously at St.
Jude’s, now at Phoenix Children’s Hospital) and were cultured in TSM media,
which consists of 50% Neurobasal-A Medium, 50% DMEM/F-12, 10 mM HEPES
solution, 1 mM MEM Sodium Pyruvate solution, 1× GlutaMAX Supplement, 1×
Antibiotic/Antimycotic solution, 1× B-27 Supplement Minus Vitamin A, 20 ng/mL
human epidermal growth factor (Shenandoah Biotech), 20 ng/mL human fibroblast
growth factor basic-154 (Shenandoah Biotech), 10 ng/mL human PDGF-AA
(Shenandoah Biotech), 10 ng/mL human PDGF-BB (Shenandoah Biotech), and
2 µg/mL heparin solution (StemCell Technologies). Cell lines were authenticated by
morphology, growth characteristics, polymerase chain reaction (PCR) for mela-
noma specific gene expression (gp100, TYRP-1, and TYRP-2) and biologic beha-
vior, tested mycoplasma-free, and frozen. Cells were cultured less than 3 months
after thawing. Cells were tested for mycoplasma using the MycoAlert Mycoplasma
Detection Kit (Lonza Rockland, Inc., ME, USA).
Immune cell activation. Spleens and lymph nodes were immediately excised from
euthanized C57Bl/6 or OT-I mice and dissociated in vitro to achieve single-cell
suspensions. Red blood cells were lysed with ACK lysis buffer (Sigma-Aldrich) for
2 min. Cells were resuspended at 1 × 106 cells/mL in Iscove’s Modified Dulbecco’s
Medium (IMDM; Gibco) supplemented with 5% FBS, 1% penicillin–streptomycin,
40 μmol/L 2-Mercaptoethanol. Cells were cocultured with target cells as described
in the text. Cell-free supernatants were then collected 72 h later and tested for IFNγ
(Mouse IFNγ ELISA Kit; OptEIA, BD Biosciences) production by ELISA as
directed in the manufacturer’s instructions.
APOBEC3 overexpression and vaccine preparation. B16TK cells were trans-
duced with a retroviral vector encoding either full length functional APOBEC3B
(APOBEC3BACTIVE) or a mutated, catalytically inactive form of APOBEC3B
(APOBEC3BINACTIVE) as a negative control obtained from Dr. Reuben Harris
(University of Minnesota, MN). Forty-eight hour post transduction with either
pBABE-Hygro APOBEC3BACTIVE or pBABE-Hygro APOBEC3BINACTIVE viruses,
bulk populations of cells were selected in hygromycin for 2 weeks and used for
experiments. Overexpression of APOBEC3B was confirmed by both Western Blot
(using a rabbit monoclonal anti-human APOBEC3B (184990, Abcam, San Fran-
cisco, CA)) and qrtPCR as previously described16. We have observed that over-
expression of APOBEC3B is toxic in that elevated levels of APOBEC3B are seen
within 72 h post transfection/transduction and return to similar levels to that seen
in parental unmodified cells. We believe this is because mutagenesis by APOBEC3B
is tolerable to the cell up to a certain threshold, and then in cells where critical
mutations are induced, this can be lethal. In other cells, overexpression of APO-
BEC3B may not reach the threshold, or mutations may not be induced in critical
genes, allowing those cells to survive carrying the APOBEC3B-induced mutations.
Consistent with this hypothesis, short term expression of APOBEC3BACTIVE, but
not the catalytically inactive mutant APOBEC3BINACTIVE, led to significant levels
of cell killing within between 72 and 96 h post transduction (Supplementary Fig. 4).
B16 or GL261 cells either left untreated, or modified to over-express either
functional APOBEC3B (B16-APOBECACTIVE) or the nonfunctional APOBEC3B
INACTIVE protein (B16-APOBEC3BINACTIVE) were expanded in T175 flasks. At
80–90% confluency, cells were trypsinized and washed three times in phosphate-
buffered saline (PBS) (HyClone). Aliquots of 5 × 107 cells were resuspended in a
volume of 1 ml PBS and then freeze–thawed for three cycles in liquid nitrogen.
Totally, 100 µl of these freeze–thawed vaccine preparations were administered
intraperitoneally (i.p.) to mice (the equivalent of 5 × 106 cells per injection).
Human cell lines were transduced with APOBEC3B or GFP using a lentiviral
vector. After 2 h, the media was replaced and cells were cultured for five more days
before use as APOBEC3B-modified or control vaccines.
In vivo experiments. All in vivo studies were approved by the Institutional Animal
Care and Use Committee at Mayo Clinic. A 6–8-week-old female C57BL/6 mice
were purchased from Jackson Laboratories (Bar Harbor, Maine). Mice were chal-
lenged subcutaneously with 2 × 105 B16TK murine melanoma cells, their APO-
BEC3BACTIVE or APOBEC3BINACTIVE derivatives, parental B16 murine melanoma
cells, or TC2 murine prostate carcinoma cells in 100 μL PBS. Alternatively, 5 × 104
GL261 cells or 1 × 104 B16 cells were implanted in 2 µL intracranially into the
brainstem. Subcutaneous tumors were treated with a two week course of GCV
(50mg/kg) administered i.p. daily; or with a 5-day course of B16-APOBEC3BACTIVE
or B16-APOBEC3BINACTIVE cell vaccines as described in the text. Subcutaneous
tumors were measured three times per week, and mice were euthanized when
tumors reached 1.0 cm in diameter. GL261 tumor cells were stereotactically
implanted into the brainstems of C57Bl/6 mice using previously published coor-
dinates of −0.8 mm on the y plane, −1 mm on the x plane, and −5 mm on the
z plane66. Intracranial tumors were treated with a 5-day course of GL261- or B16-
APOBEC3BACTIVE or APOBEC3BINACTIVE cell vaccines as described in the text.
Mice were sacrificed upon emergence of neurological symptoms or weight loss.
Immune cell depletions and checkpoint inhibition. To deplete specific immune
subsets, mice were treated with intraperitoneal (i.p.) injections (0.1 mg per mouse)
of anti-CD8 (Lyt 2.43, BioXCell), anti-CD4 (GK1.5, BioXCell), anti-NK (anti-
asialo-GM-1, Cedarlane), and IgG control (ChromPure Rat IgG, Jackson Immu-
noResearch) at day 4 after tumor implantation and then weekly thereafter.
Fluorescence-activated cell sorting analysis of spleens and lymph nodes confirmed
subset specific depletions. For immune checkpoint blockade, mice were treated
intravenously with anti-PD1 (0.25 mg; catalog no. BE0146; Bio X Cell), anti-CTLA-
4 (0.1 mg; catalog no. BE0164; Bio X Cell), anti-asialo GM1 (0.1 mg; catalog no.
CL8955; Cedarlane), or isotype control rat IgG (catalog no. 012-000-003; Jackson
ImmunoResearch) antibody at times described in each experiment.
Next generation sequencing. DNA for whole-genome sequencing was prepared
from B16tk cells that overexpressed either APOBEC3BACTIVE or parental,
unmodified cells. These cells were generated initially from an experiment investi-
gating the role of APOBEC3B overexpression on the generation of resistance to
VSV oncolysis16. Following three rounds of infection with VSV, genomic DNA was
isolated from APOBEC3B expressing cells resistant to infection or parental, mock-
infected cells. Five hundred nanograms of each sample was prepared using an Ultra
kit (New England Bio) and underwent paired end 150 bp sequencing on the Illu-
mina HiSeq 4000 by Mayo’s Genome Analysis Core. Sequences were aligned to the
mm10 C57Bl/6 genome by the Mayo’s Bioinformatics Core Facility and mutational
changes were detected between the two samples. These mutations contained 244C
to T or G to A missense mutations which were unique to the APOBEC3BACTIVE
line. These coding variants were filtered through NET MHC 2.0 binding affinity
algorithm to identify octamer or nonamer peptides whose binding affinity for
H2Kb or H2Kd was below a threshold of 500 nM, and whose corresponding wild-
type peptides had a binding affinity to the same molecules above 500 nM. A list of
36 candidates was further refined using the EMBL-EBI Expression Atlas for
expression in skin tissue to identify 10 high affinity APOBEC3B- induced het-
eroclitic peptides.
APOBEC3B-modified epitope expression. cDNAs encoding either wild type
(unmutated) or APOBEC3B-mutated 9 mer peptides derived from the screen
described above were synthesized and cloned into the plasmid pcDNA3.1+ P2A-
eGFP (Genescript), where the cDNA is expressed from a CMV promoter and co-
expressed with an eGFP protein. pcDNA3.1-EPITOPE+ P2A-eGFP plasmids were
transfected into B16 cells using Lipofectamine. Cultures in which transfection of
over 50% of cells was confirmed by GFP analysis 48–72 h post transfection were
used either as targets in immune activation assays (above) or were expanded in
T175 flasks. At 80–90% confluency, cells were trypsinized and washed three times
in PBS. Aliquots of 5 × 107 cells were resuspended in a volume of 1 ml PBS and
then freeze–thawed for three cycles in liquid nitrogen. Totally, 100 µl of these
freeze–thawed vaccine preparations were administered intraperitoneally to mice
(the equivalent of 5 × 106 cells per injection).
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Human T cell in vitro education and restimulation. Fresh PBMCs from a healthy
donor were acquired from the Mayo Clinic Blood Bank. CD3+ T cells were isolated
using a magnetic sorting kit (Miltenyi Biotech) and activated using CD3/CD28
beads (ThermoFisher). T cells were immediately cocultured at a ratio of 10:1 with
interferon gamma pretreated (200 U/mL for 12 h) APOBEC3B or GFP-transduced
Mel888 cells. After 10 days of coculture, CD3+ T cells were re-isolated using a
magnetic sorting kit (Miltenyi Biotech) and labeled with Cell Trace Violet (Ther-
moFisher) for proliferation analysis. These T cells were then cocultured with
interferon gamma pretreated (200 U/mL for 12 h) parental Mel888 cells for 72 h,
followed by interferon gamma ELISA (R&D), flow cytometric proliferation analysis
via cell trace violet dilution, and counting of remaining Mel888 cells.
For vaccination with SJPDGF1 tumors, T cells were isolated and activated as
described above. Autologous monocyte-derived dendritic cells were matured by
isolating CD14+ cells by magnetic sorting (Miltenyi Biotech), followed by
incubation with human granulocyte-macrophage colony-stimulating factor
(GM-CSF) (800 U/mL) and IL-4 (1000 U/mL). On Days 3 and 5, media was
replaced with human GM-CSF (1600 U/mL) and IL-4 (1000 U/mL). On Day 7,
non-adherent cells were collected, washed with PBS, and resuspended in medium
containing GM-CSF (800 U/mL), IL-4 (1000 U/mL), TNF-alpha (1100 U/mL),
IL-1beta (1870 U/mL), IL-6 (1000 U/mL), and PGE2 (1 µg/mL). Two days later,
dendritic cells were harvested for co-incubation with activated T cells at a ratio of
1:10. On each of the first 3 days of coculture, SJPDGF1-GFP, Mel888-GFP, or
SJPDGF1-APOBEC3B cell lysates were added to the coculture. Ten days after
initial coculture, CD3+ T cells were isolated using magnetic bead sorting (Miltenyi
Biotech), cocultured with newly matured monocyte-derived dendritic cells, and fed
with parental SJPDGF1 lysate. Three days later, supernatant was collected for
interferon gamma ELISA (R&D).
Cytidine deamination assay. Lysates of un-transduced (UTD) parental, APO-
BEC3BACTIVE or APOBEC3BINACTIVE cells were incubated for 2 h at 37 °C with a
43 bp fluorescein labeled probe. APOBEC3B present in the lysate will deaminate
the single C to a U and in the presence of 6N NaOH the U-containing substrate
will be cleaved into 30 bp (labeled) and 12 bp (unlabeled) products which could be
visualized on a 15% TBE-Urea polyacrylamide gel electrophoresis gel67.
Statistics. Survival curves were analyzed by the Log-Rank test with
Holm–Bonferroni correction for multiple comparisons. Student’s t tests, one-way
ANOVA and two-way ANOVA were applied for in vitro assays as appropriate.
Statistical significance was set at p < 0.05 for all experiments.
Primer sequences. CSDE1* sequencing 5′-TCACGAAGTGCTGCTGAAGT-3′
APOBEC3B qRT-PCR Forward 5′-ATGAATCCACAGATCAGAAATCCG-3′
APOBEC3B qRT-PCR Reverse 5′-GGTAATCTCTTTCCCAGTAGTAGT-3′
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data are available in the Article, Supplementary Information or from the
corresponding author upon request. Binary sequence alignments/map files can be
accessed using the NIH Sequence Read Archive: SRP159367.
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